| The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor–positive metastatic breast cancer SA Wander, O Cohen, X Gong, GN Johnson, JE Buendia-Buendia, ... Cancer discovery 10 (8), 1174-1193, 2020 | 216 | 2020 |
| Serine/threonine kinase 17A is a novel p53 target gene and modulator of cisplatin toxicity and reactive oxygen species in testicular cancer cells P Mao, MP Hever, LM Niemaszyk, JM Haghkerdar, EG Yanco, D Desai, ... Journal of Biological Chemistry 286 (22), 19381-19391, 2011 | 113 | 2011 |
| Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer P Mao, O Cohen, KJ Kowalski, JG Kusiel, JE Buendia-Buendia, ... Clinical Cancer Research 26 (22), 5974-5989, 2020 | 111 | 2020 |
| Serine/threonine kinase 17A is a novel candidate for therapeutic targeting in glioblastoma P Mao, MP Hever-Jardine, GJ Rahme, E Yang, J Tam, A Kodali, B Biswal, ... PLoS One 8 (11), e81803, 2013 | 85 | 2013 |
| Abstract PD4-01: The role of FGF/FGFR axis in resistance to SERDs and CDK4/6 inhibitors in ER+ breast cancer P Mao, J Kusiel, O Cohen, N Wagle Cancer Research 78 (4_Supplement), PD4-01-PD4-01, 2018 | 14 | 2018 |
| Cell Line–Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations J Gómez Tejeda Zañudo, P Mao, C Alcon, K Kowalski, GN Johnson, G Xu, ... Cancer research 81 (17), 4603-4617, 2021 | 12 | 2021 |
| Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors … SA Wander, O Cohen, GN Johnson, D Kim, F Luo, P Mao, U Nayar, ... Journal of Clinical Oncology 36 (15_suppl), 12016-12016, 2018 | 12 | 2018 |
| Headway and hurdles in the clinical development of dietary phytochemicals for cancer therapy and prevention: lessons learned from vitamin A derivatives CY Yim, P Mao, MJ Spinella The AAPS journal 16, 281-288, 2014 | 9 | 2014 |
| The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer … SA Wander, O Cohen, X Gong, GN Johnson, JE Buendia-Buendia, ... CD-19-1390, 2020 | 5 | 2020 |
| Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+ … SA Wander, O Cohen, X Gong, GN Johnson, J Buendia-Buendia, M Lloyd, ... Cancer Research 80 (4_Supplement), PD2-09-PD2-09, 2020 | 4 | 2020 |
| Abstract PD7-08: Igf1r mediates cdk4/6 inhibitor (cdk4/6i) resistance in tumor samples and in cellular models SA Wander, P Mao, MR Lloyd, GN Johnson, K Kowalski, U Nayar, ... Cancer Research 81 (4_Supplement), PD7-08-PD7-08, 2021 | 3 | 2021 |
| Abstract PD9-02: Evolutionary analysis of 462 serial metastatic biopsies from 208 patients with estrogen receptor-positive (ER+) metastatic breast cancer (MBC) using whole … O Cohen, J Buendia-Buendia, S Wander, U Nayar, P Mao, A Waks, D Kim, ... Cancer Research 79 (4_Supplement), PD9-02-PD9-02, 2019 | 2 | 2019 |
| Abstract PS5-10: Esr1 mutation as a potential predictor of abemaciclib benefit following prior cdk4/6 inhibitor (cdk4/6i) progression in hormone receptor-positive … SA Wander, HS Han, GN Johnson, MR Lloyd, P Mao, U Nayar, ... Cancer Research 81 (4_Supplement), PS5-10-PS5-10, 2021 | 1 | 2021 |
| Esr1 mutation as a potential predictor of abemaciclib benefit following prior cdk4/6 inhibitor (cdk4/6i) progression in hormone receptor-positive (hr plus) metastatic breast … SA Wander, HS Han, GN Johnson, MR Lloyd, P Mao, U Nayar, ... CANCER RESEARCH 81 (4), 2021 | 1 | 2021 |
| Abstract P3-03-08: a large-scale functional screen to identify resistance mechanisms to selective estrogen receptor degraders fulvestrant and GDC-810 in ER+ breast cancer P Mao, Q Quartey, O Cohen, F Piccioni, N Wagle Cancer Research 77 (4_Supplement), P3-03-08-P3-03-08, 2017 | 1 | 2017 |
| STK17A is a potential therapeutic target in glioblastoma P Mao, MP Jardine, GJ Rahme, EC Yang, J Tam, A Kodali, B Biswal, ... Cancer Research 74 (19_Supplement), 4605-4605, 2014 | 1 | 2014 |
| The novel protein kinase STK17A is a direct p53 target gene that mediates response to genotoxic and nutritional stress in a cancer cell context-dependent manner P Mao, M Jardine, L Niemaszyk, J Haghkerdar, E Yang, EG Yanco, ... Cancer Research 72 (8_Supplement), 2958-2958, 2012 | 1 | 2012 |
| Cell-line-specific network models of ER+ breast cancer identify PI3Kα inhibitor sensitivity factors and drug combinations JGT Zañudo, P Mao, C Alcon, KJ Kowalski, GN Johnson, G Xu, J Baselga, ... bioRxiv, 0 | 1 | |
| Cell line-specific network models of ER+ breast cancer identify PI3Kα inhibitor sensitivity factors and drug combinations JG Tejeda Zañudo, P Mao, C Alcon, KJ Kowalski, GN Johnson, G Xu, ... bioRxiv, 2020.08. 25.261370, 2020 | | 2020 |
| Abstract P6-10-08: AKT1 alterations following exposure to endocrine-based therapy in patients with hormone-receptor positive (HR+) metastatic breast cancer … S Wander, P Mao, M Lloyd, K Kowalski, GN Johnson, G Malvarosa, B Moy, ... Cancer Research 80 (4_Supplement), P6-10-08-P6-10-08, 2020 | | 2020 |
